
The CLL expert spoke about the implications of this study for patients and how patients can apply this knowledge to their own course of treatment.

Your AI-Trained Oncology Knowledge Connection!


The CLL expert spoke about the implications of this study for patients and how patients can apply this knowledge to their own course of treatment.

The chronic lymphocytic leukemia expert spoke about the possible use of venetoclax plus dose-adjusted R-EPOCH in various hematologic patient populations.

A multicenter phase 2 study of patients with chronic lymphocytic leukemia who developed Richter’s syndrome, presented at the 2020 ASCO Virtual Scientific Program, assessed the use of this treatment combination.

The study evaluated venetoclax plus dose-adjusted R-EPOCH in patients with chronic lymphocytic leukemia who developed Richter’s syndrome.

The CLL expert discussed the possibility of venetoclax plus dose-adjusted R-EPOCH becoming a new treatment approach in patients with CLL who developed Richter’s Syndrome.

Published: June 21st 2020 | Updated:

Published: July 11th 2020 | Updated:

Published: July 26th 2020 | Updated:

Published: June 12th 2020 | Updated:

Published: June 1st 2020 | Updated: